Stable Value Consultants Open for Business

Chris Tobe has started a niche consulting firm that works primarily on stable value.

Stable Value Consultants will do project, hourly, and retainer consulting for plans, collective trusts and the stable value industry.  The firm is set up to help plans minimize their liability in their stable value option, while providing solid returns above money market, according to an announcement. 

Tobe also has a new white paper titled “Financial Crisis and Subsequent Regulations effect on Stable Value.” The paper states that although stable value is 20% to 40% of assets in many DC plans, most general consultants only have a superficial knowledge of stable value.  It cites a recent survey from July 2010 that shows that 46% of plans feel they need to address the increased scrutiny around Stable Value Plans.

Never miss a story — sign up for PLANADVISER newsletters to keep up on the latest retirement plan adviser news.

The paper is available by request by email: ctobe@stablevalueconsultants.com.

 

Law Firm Investigates Potential ERISA Violations by GlaxoSmithKline

Holzer Holzer & Fistel, LLC is investigating potential violations of the Employee Retirement Income Security Act (ERISA) by GlaxoSmithKline plc. 

A press release said the investigation focuses on whether GlaxoSmithKline properly managed the Company’s 401(k) plan and whether certain administrators of the plan complied with their fiduciary duties to prudently manage the plan.   

The law firm is asking current or former participants of the GlaxoSmithKline 401(k) plan to contact attorneys Michael I. Fistel Jr., Esq. or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via telephone at (888) 508-6832.   

Never miss a story — sign up for PLANADVISER newsletters to keep up on the latest retirement plan adviser news.

More about the firm’s investigations is at www.holzerlaw.com. 

Last week, law firm Stull, Stull & Brody also announced it is investigating the drugmaker for potential ERISA violations (see Law Firm Probes Drugmaker for 401(k) Missteps). 

 

«